Abstract: The use of complex coacervates of two or more biopolymer materials, preferably at least one of these being gelatin, as a fat-replacing ingredient. The complex coacervates may be used in foods and cosmetics and preferably are of substantially spherical or elliptical shape and have an average D.sub.3,2 particle size, of from 0.2 to 100 microns.
Type:
Grant
Filed:
April 10, 1996
Date of Patent:
September 14, 1999
Assignee:
Van den Bergh Foods Co.
Inventors:
Marinus Adriaan Bakker, Mettina Maria Koning, Johannes Visser
Abstract: An oral pharmaceutical preparation containing a therapeutically effective amount of a salt of morphine for administration once daily is provided. The preparation contains particles which have a core containing a salt of morphine coated with a barrier layer. The barrier layer is formed from a coating liquid that contains at least one water insoluble barrier forming component selected from the group consisting of ethyl cellulose, copolymers of acrylic and methacrylic esters and natural or synthetic waxes, and a plasticizer. The mean serum concentration of morphine obtained is at least 50% of the maximum serum concentration during at least 12 hours after the administration of a single dose of the preparation.
Type:
Grant
Filed:
April 21, 1997
Date of Patent:
September 14, 1999
Assignee:
Pharmacia & Upjohn Aktiebolag
Inventors:
Birgitta Olsson, Maritta Anneli Pesonen, Gert Ragnarsson
Abstract: The present invention is a method for enhancing the analgesic efficacy of a locally applied opioid analgesic or local anesthetic agent in a mammal having an impermeable perineurium barrier sheet about the peripheral sensory nerves at the site of action of the analgesic or anesthetic agent. The method involves applying to that site an effective amount of the analgesic or anesthetic agent dissolved in a hyperosmolar solution having an osmolality of above 300 mOsm/l.
Abstract: A method of delivering a cosmetic agent to the body, comprising electrostatically spraying thereon a cosmetic composition comprising said cosmetic agent, the composition having a resistivity of less than 10.sup.4 ohm cm. Apparatus for carrying out the method comprises a reservoir for the composition, delivery means, a voltage generator, and control means for applying the voltage from the generator to the delivery means to electrostatically spray the composition. The cosmetic agent may comprise an antiperspirant or other type of personal cosmetic product.
Abstract: This invention provides a deodorant-antiperspirant composition in a dispensing container pressurized with an aerosol propellant. The primary ingredients of a typical product are particulate sodium bicarbonate, particulate antiperspirant astringent salt, volatile silicone oil, carboxylate ester emollient, and a suspending agent such as hydrophobic hectorite clay. An invention aerosol deodorant-antiperspirant product has a stable particulate sodium bicarbonate and astringent salt suspension phase. The odor and wetness reduction properties of the product during underarm application are enhanced by the micronized form of the astringent salt ingredient, and by the controlled ratio of volatile oil to emollient in the product.
Abstract: Improved aqueous gliadin-containing cosmetic formulations are provided which include form about 0.5-10% by weight gliadin dispersed in an aqueous solvent system together with additional ingredients giving desired end properties. The formulations are preferably selected from the group consisting of hairsprays, hair shampoos and shampoo conditioners, hair styling gels, hair conditioners, instant conditioners, and hair reparatives, as well as sunscreens, shaving creams and bath and shower gels.
Type:
Grant
Filed:
October 24, 1997
Date of Patent:
August 31, 1999
Assignee:
Midwest Grain Products
Inventors:
Sukh Bassi, Larry Murphy, Clodualdo C. Maningat, Li Nie
Abstract: Various preparations for treating or relieving pain in a patient are disclosed wherein preparations containing caesium ions, preferably in the form of caesium chloride, and preferably also magnesium ions in the form of magnesium sulphate, are administered externally or internally to the patient. In one preferred embodiment a topical preparation is provided which consists of strips of microporous material (A) on each side of a plastics backing layer (B) impregnated with an aqueous solution containing caesium chloride and magnesium sulphate. In an alternative embodiment a cream preparation containing caesium chloride and magnesium sulphate is provided for external application to the patient.
Abstract: The invention is directed to an improved system for controlled release of biologically active materials and to a liquid composition for its formation. The liquid composition is composed of a thermoplastic polymer, rate modifying agent, bioactive material and organic solvent. The liquid composition is capable of forming a biodegradable and/or bioerodible microporous, solid polymer matrix. The matrix is useful as an implant in patients (humans and animals) for delivery of biologically active substances to tissues or organs.
Abstract: A pharmaceutical formulation comprises, in an amount effective to hydrate lung mucous secretions, a compound of Formula (I): ##STR1## wherein n is from 1 to 6;X is --OH or --SH;A and B are each independently selected from the group consisting of: ##STR2## wherein R is H or Br; or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A method of hydrating mucous secretions in the lungs of a subject in need of such treatment, comprising administering to the lungs of the subject a compound of Formula I as given above, is also disclosed.
Type:
Grant
Filed:
May 8, 1997
Date of Patent:
August 10, 1999
Assignee:
The University of North Carolina at Chapel Hill
Inventors:
Monroe Jackson Stutts, III, Richard C. Boucher, Jr., Eduardo R. Lazarowski, Cara A. Geary
Abstract: A dispenser for space spraying an aerosol composition comprising a container for containing the aerosol composition and a metering device for space spraying a metered amount of he composition. The composition comprises active ingredient and propellant wherein the propellant is dissolved in the active ingredient. In preferred form, the composition comprises a non-aqueous solution containing 10-85% w/w active ingredient, 1-25% w/w co-solvent and 15-80% w/w propellant.
Abstract: A stable solution, cream, salve, or spray composition containing activated chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the treatment of vaginitis and endometriosis by reducing any of Candida, Actinobacillus actinomycetemcomitans, Pseudomonades, and Porphyromonas gingivalis present in the vagina or the uterus. The preferred concentration ranges are in the range of about 0.005% to about 2.0% of chlorine dioxide, and in the range of about 0.02% to about 3.0% of phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.4, at which pH chlorine dioxide becomes activated and releases sufficient chlorine dioxide to reduce motility and become lethal to the involved micro-organisms.
Abstract: Nanosols and process for preparing the same allow colloidally dispersed solutions of scarcely water-soluble active substances to be stabilized with gelatin or its derivatives, by partly or fully setting the iso-ionic point (IIP, equivalent to a neutral charge) between the gelatin and the surface charged active substance particles. In order to neutralize the charge of the system composed of active substance particles and gelatin, the surface charge of the particles is compensated by a corresponding opposite charge of the gelatin molecules. For that purpose, a determined charge in relation to the isoelectric point (IEP) and the pH value of the solution is set on the gelatin molecules. By stabilizing in this way the practically monodispersed state thus generated, the Ostwald maturation of the colloidal particles of scarcely soluble active substance is strongly reduced.
Abstract: An improved method of treating psoriasis involves controlling the enhanced proliferation and terminal differentiation of psoriatic epidermis through the activity of epidermal phosphorylase kinase. In general, the method involves contacting psoriatic epidermal cells with a combination of substances affecting the activity of phosphorylase kinase. The combination can be: (1) a calmodulin inhibitor together with a stimulator of cAMP-dependent protein kinase II, (2) a calmodulin inhibitor together with a calcium channel blocker; (3) a stimulator of cAMP-dependent protein kinase II together with a calcium channel blocker; or (4) a calmodulin inhibitor together with a calcium channel blocker and a stimulator of cAMP-dependent protein kinase II. Alternatively, a selective phosphorylase kinase inhibitor such as curcumin can be administered, alone or with an agent such as vitamin D.sub.3 or an analogue thereof, etretinate, diltiazem, or anthralin. The invention also includes pharmaceutical compositions.
Abstract: This disclosure is of a surfactant mixed with an aerosollizing agent, and deposited by such agent, as a treatment for airway obstruction. It has been extensively tested, and has proved successful. It has been hypothesized that the addition of a hypersmolor drug will help to minimize mucus in the airways.
Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when said formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.
Type:
Grant
Filed:
April 15, 1998
Date of Patent:
July 13, 1999
Assignee:
Glaxo Group Limited
Inventors:
Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
Abstract: Blends of polymers having properties distinct from the individual polymer components and that are suitable for use as carriers of pharmaceutically active agents, are prepared from two or more polyanhydrides, polyesters or mixtures of polyanhydrides and polyesters. The blends have different properties than the polymers used to prepare the blends, providing a means for altering the characteristics of a polymeric matrix without altering the chemical structure of the component polymers. Blends of various polyanhydrides, polyesters, and polyanhydrides and polyesters, containing pharmaceutically active agents, are prepared using solvent mixing or melt mixing procedures.
Type:
Grant
Filed:
December 23, 1992
Date of Patent:
July 6, 1999
Assignee:
Massachusetts Institute of Technology
Inventors:
Abraham J. Domb, Manoj Maniar, Andrew S. T. Haffer
Abstract: This invention provides an antioxidant-containing effervescent composition comprising, as essential components, 0.05 to 15% by weight of an antioxidant-containing powder, 10 to 35% by weight of sodium hydrogencarbonate and/or sodium carbonate, 10 to 70% by weight of a neutralizing agent and 30 to 55% by weight of an excipient. The antioxidant-containing effervescent composition of the invention stably contains an antioxidant and is excellent in solubility.
Abstract: The present application relates to aerosol formulations comprising (1) a medicament in particulate form and having a surface coating of a surfactant, (2) a hydrogen-containing fluorocarbon or chlorofluorocarbon propellant, and (3) a co-solvent having higher polarity than the propellant, which cosolvent is present in an amount of up to 5% w/w based upon propellant. The invention also relates to methods for preparation of these aerosol formulations.
Type:
Grant
Filed:
May 12, 1995
Date of Patent:
July 6, 1999
Assignee:
Glaxo Group Limited
Inventors:
Anthony James Taylor, Patricia Kwong Phieu Burnell
Abstract: A simulated capsule-like medicament comprising a subcoating of a mixture of a water-soluble, film-forming polymer, e.g. hydroxypropylmethyl cellulose and a hydrophobic plasticizer e.g. castor oil, which promotes a smooth uniform and substantially bubble free outer coating, e.g. gelatin, for the capsule-like medicament; capsule-like medicaments which are slightly bowed in shape; and a process of making such medicaments.
Type:
Grant
Filed:
February 18, 1997
Date of Patent:
June 29, 1999
Assignee:
McNeil-PPC, Inc.
Inventors:
Kishor B. Parekh, Dennis C. Wieand, Jean B. Leasure
Abstract: A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.
Type:
Grant
Filed:
April 6, 1998
Date of Patent:
June 29, 1999
Assignee:
Glaxo Group Limited
Inventors:
Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt